Evidence map›Paper›PMID 29066877›Full record

Trial reportClinical interventions in aging2017

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study.

Chunyan Lu, Yun Chen, Bin Zhang, Yu Chen, Fan Bai, Decai Chen

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical interventions in aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Calcitonin: A useful old friend.Journal of musculoskeletal & neuronal interactions · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chunyan LuDepartment of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
Yun ChenLilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.
Bin ZhangLilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.
Yu ChenLilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.
Fan BaiLilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.
Decai ChenDepartment of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Teriparatide is the first anabolic agent for osteoporosis, and this analysis aimed to understand responses to teriparatide in Chinese patients with established osteoporosis in subgroups. In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks. Teriparatide treatment produced a significantly greater increase in lumbar spine bone-mineral density (LS-BMD) in postmenopausal women than calcitonin at the 24-week end point. The relationship between osteocalcin (OCN) and LS-BMD was evaluated, and the greatest correlation was found between absolute OCN change at week 12 and percentage change in LS-BMD for patients in the teriparatide group (

Indexed as

AgedBone DensityBone Density Conservation AgentsCalcitoninChinaFemaleHumansLumbar VertebraeOsteocalcinOsteoporosis, PostmenopausalTeriparatideBone Density Conservation AgentsCalcitoninOsteocalcinsalmon calcitoninTeriparatidelumbar spine bone-mineral densityosteocalcinosteoporosisteriparatide

Identifiers

PMID29066877
PMCPMC5644555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.